| Naslov: | Establishment of ELISA-comparable moderate and high thresholds for anticardiolipin and anti-β2 glycoprotein I chemiluminescent immunoassays according to the 2023 ACR/EULAR APS classification criteria and evaluation of their diagnostic performance |
|---|
| Avtorji: | ID Žigon, Polona (Avtor)
ID Boštic, Nika (Avtor)
ID Ambrožič, Aleš (Avtor)
ID Rotar, Žiga (Avtor)
ID Blokar, Elizabeta (Avtor)
ID Ogrič, Manca (Avtor)
ID Čučnik, Saša (Avtor) |
|---|
| Datoteke: |  PDF - Predstavitvena datoteka, prenos (1,19 MB)
MD5: 3C941B318F1C3CEFC25E85E7DEFD8897
 URL - Izvorni URL, za dostop obiščite https://www.degruyter.com/document/doi/10.1515/cclm-2024-0570/html
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.01 - Izvirni znanstveni članek |
|---|
| Organizacija: |  UKC LJ - Univerzitetni klinični center Ljubljana
|
|---|
| Povzetek: | Objectives: Recently published 2023 ACR/EULAR APS classification criteria emphasize the importance of quantifying single-, double-, and triple-antiphospholipid antibody positivity, distinguishing between IgG and IgM isotypes, and delineating moderate/high levels of anticardiolipin (aCL) and anti-β2 glycoprotein I (anti-β2GPI) antibodies. We aimed to establish clinically important moderate/high thresholds for aCL and anti-β2GPI IgG/IgM chemiluminescent immunoassays (CLIA), in particular QUANTA Flash, comparable to our in-house ELISAs used for over two decades, and to evaluate their diagnostic performance. Methods: QUANTA Flash CLIA and in-house ELISAs were used to measure aCL and anti-β2GPI IgG/IgM. Moderate thresholds for QUANTA Flash CLIA were determined using a non-parametric approach, calculating a 99th percentile on serum samples from 139 blood donors, and by mirroring the diagnostic performance of in-house ELISA on 159 patient samples. Results: Thresholds for QUANTA Flash CLIA achieving diagnostic performance equivalent to in-house ELISAs were 40 CU for moderate and 80 CU for high levels for aCL and anti-β2GPI IgG and IgM. The assays showed good qualitative agreement, ranging from 76.10 to 91.19 %. When considering in-house ELISA results, 14 out of 80 (17.5 %) patients did not fulfill the new ACR/EULAR laboratory classification criteria, while 27 out of 80 (33.8 %) did not when considering QUANTA Flash CLIA results. Conclusions: We determined moderate and high thresholds for aCL and anti-β2GPI IgG and IgM detected with QUANTA Flash CLIA, aligning with long-established in-house ELISA thresholds. These thresholds are crucial for seamlessly integrating of the new 2023 ACR/EULAR classification criteria into future observational clinical studies and trials. |
|---|
| Ključne besede: | anti-β2GPI, anticardiolipin, antiphospholipid syndrome, classification criteria |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Leto izida: | 2025 |
|---|
| Št. strani: | str. 164-176 |
|---|
| Številčenje: | Vol. 63, iss. 1 |
|---|
| PID: | 20.500.12556/DiRROS-24057  |
|---|
| UDK: | 616-097 |
|---|
| ISSN pri članku: | 1437-4331 |
|---|
| DOI: | 10.1515/cclm-2024-0570 |
|---|
| COBISS.SI-ID: | 203693059 |
|---|
| Opomba: | Nasl. z nasl. zaslona;
Opis vira z dne: 5. 1. 2025;
|
|---|
| Datum objave v DiRROS: | 10.11.2025 |
|---|
| Število ogledov: | 152 |
|---|
| Število prenosov: | 74 |
|---|
| Metapodatki: |    |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
